Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone : analyses from the Phase II HORIZON study - Larocca, Alessandra (Azienda Ospedaliero - Universitaria Città della Salute e della Scienza) ; Leleu, Xavier (CHU de Poitiers) ; Touzeau, Cyrille (Université d'Angers) ; Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Paner, Agne (Rush University Medical Center) ; Mateos, M. V (Instituto de Investigación Biomédica de Salamanca) ; Cavo, Michele (Bologna University School of Medicine) ; Maisel, Christopher (Baylor Scott & White Charles A) ; Alegre, Adrian (Hospital Universitario de la Princesa (Madrid)) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Raptis, Anastasios (niversity of Pittsburgh School of Medicine) ; Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ; Mazumder, Amitabha (The Oncology Institute of Hope and Innovation) ; Laubach, Jacob (Harvard Medical School) ; Nadeem, Omar (Harvard Medical School) ; Sandberg, Anna (Oncopeptides AB (Suècia)) ; Orre, Marie (Oncopeptides AB (Suècia)) ; Torrång, Anna (SDS Life Science (Suècia)) ; Bakker, Nicolaas A (Oncopeptides AB) ; Richardson, Paul G.. (Harvard Medical School) ; Universitat Autònoma de Barcelona
 
Comments (0) | Reviews (0)
Start a discussion about any aspect of this document.

 Subscribe to this discussion. You will then receive all new comments by email.

Add comment


Once logged in, authorized users can also attach files.
Note: you have not defined your nickname.
N/D will be displayed as the author of this comment.
          You can use some HTML tags: <a href>, <strong>, <blockquote>, <br />, <p>, <em>, <ul>, <li>, <b>, <i>